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Abstract: Ovarian cancer (OC) is the most lethal female gynecological malignancy, mostly due to
diagnosis in late stages when treatment options are limited. Hedgehog-GLI (HH-GLI) signaling
is a major developmental pathway involved in organogenesis and stem cell maintenance, and is
activated in OC. One of its targets is survivin (BIRC5), an inhibitor of apoptosis protein (IAP) that
plays a role in multiple processes, including proliferation and cell survival. We wanted to investigate
the role of different GLI proteins in the regulation of survivin isoform expression (WT, 2α, 2B, 3B,
and ∆ex3) in the SKOV-3 OC cell line. We demonstrated that survivin isoforms are downregulated in
GLI1 and GLI2 knock-out cell lines, but not in the GLI3 knock-out. Treatment of GLI1 knock-out cells
with GANT-61 shows an additional inhibitory effect on several isoforms. Additionally, we examined
the expression of survivin isoforms in OC samples and the potential role of BIRC5 polymorphisms
in isoform expression. Clinical samples showed the same pattern of survivin isoform expression as
in the cell line, and several BIRC5 polymorphisms showed the correlation with isoform expression.
Our results showed that survivin isoforms are regulated both by different GLI proteins and BIRC5
polymorphisms in OC.
Keywords: Hedgehog signaling; GLI proteins; survivin; ovarian cancer; isoform expression; polymorphisms
1. Introduction
Most malignant ovarian tumors in adult women are epithelial ovarian tumors. These neoplasms
are classified into different morphological categories according to the appearance of epithelial
cells in serous, mucinous, endometrial, clear cell carcinomas, mixed, squamous, transient, and
non-differentiated tumors [1]. Serous adenocarcinomas are the most common and make up 75%
of all ovarian cancer. Each histological type of ovarian tumor and the degree of differentiation of the
cells is associated with certain molecular-genetic changes.
The Hedgehog signaling pathway is a developmental pathway involved in formation of various
tissues and organs, including the ovary. In mammals, canonical signal transduction is triggered by
binding of the ligand Hedgehog (HH) to the transmembrane receptor Patched (PTCH). This leads to
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receptor internalization and exposure of the protein Smoothened (SMO) on the cell surface. Activation
of SMO triggers the release of transcription factors GLI (GLI1-3) from Suppressor of Fused (SUFU)
and the translocation of GLI to the nucleus. GLI, then, activates transcription of HH target genes
which are involved in cell cycle regulation, proliferation, adhesion, epithelial-mesenchymal transition,
self-renewal, and pathway autoregulation [2,3]. Recently, survivin has also been identified as a novel
HH target gene. Vlcˇková et al demonstrated that expression of survivin is directly regulated by
GLI2, more specifically by the GLI2∆N isoform [4]. A study by Brun et al showed that survivin is
overexpressed in HH-driven medulloblastoma. They suggest it may represent a novel therapeutic
target for this disease [5].
Survivin is the smallest member of the inhibitors of apoptosis (IAP) family of proteins in
mammals [6]. The gene for survivin, BIRC5 (baculoviral IAP repeat containing 5), is located on
human chromosome 17q25 [7]. The BIRC5 gene has four dominant exons (1, 2, 3, and 4) and two
cryptic exons (2B and 3B). Alternative splicing of its pre-mRNA produces at least five different mRNAs
encoding five different proteins with different intracellular distribution and anti-apoptotic properties:
wild type survivin (S WT), survivin 2α (S 2α), survivin 2B (S 2B), survivin 3B (S 3B), and survivin-∆Ex3
(S ∆Ex3) (Figure 1) [8].
Figure 1. The exon structure of five splice isoforms of survivin. Exons are drawn relative to their size.
Vertical bars indicate the site of stop codon of each isoform.
S WT, discovered in 1997, contains a BIR domain necessary for its anti-apoptotic function [9].
It is expressed during development but is not expressed in most differentiated adult tissues.
The overexpression of survivin is common in almost all tumors and is indicative of decreased overall
survival, increased rate of recurrence, and resistance to therapy [6].
S 2α is the smallest isoform with a truncated BIR domain [10]. The reports about its function in
cancer is conflicting, while some studies report that it binds to and attenuates anti-apoptotic activity of
WT survivin or correlates with expression in lower stages of the disease [8,10], other studies report its
association with resistance to treatment [11,12].
S 2B is the longest survivin isoform, but the insertion of cryptic exon 2B interrupts the BIR
domain [13]. Its function remains unclear. While some studies report that it promotes cell death, or
that its expression is inversely correlated with the tumor stage [8,11,14–17], others report its expression
being correlated with treatment resistant cancers [18].
S 3B lacks the carboxyl-terminal coiled-coil domain of WT survivin [19]. It is considered
cytoprotective [20,21] and its overexpression has been correlated with shorter overall survival and
resistance to therapy [11,22].
S ∆ex3 contains a bipartite nuclear localization signal (NLS) and localizes to nucleus in cancer
cells [23,24]. Its expression in tumors is associated with aggressive disease and unfavorable
prognosis [24,25].
Survivin exhibits cell-cycle-dependent expression that is mostly controlled at transcription level.
Its accumulation during mitosis is also influenced by posttranslational modifications that affect its
stability. When expressed during mitosis, it is located in various sections of the mitotic apparatus
such as centrosomes, microtubules, and anaphase spindles, and remains of the mitotic apparatus [6].
The homologous deletion of survivin results in early embryo death, which shows its crucial role
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in cellular development, differentiation, and homeostasis. It is selectively expressed in cancer cells,
but not in healthy tissues. Excess accumulation of survivin is associated with the development of
disease, disease recovery, and prognosis in various cancers, including bladder cancer, cervix, head and
neck, prostate, skin, and ovarian [7]. A global deregulation of the BIRC5 gene mediated by oncogenes
(including STAT3, E2F or mutated RAS) or by the loss of tumor suppressors such as p53 or APC,
accounts for the selective expression of survivin in cancer [26]. Since survivin is expressed exclusively
in cancer cells, it is an interesting target for targeted therapy and new methods for detection of survivin,
as well as new inhibitors, are constantly being developed [18,26–28].
Several BIRC5 polymorphisms have been studied and have been associated with susceptibility to
lung [29], gastric [30], bladder [31], oral [32], and liver cancer [33] as well as age of onset in ovarian
cancer [7] and survival in colorectal cancer [8] and breast cancer [34].
X-ray crystallography has shown that survivin is organized as a dimer [6]. Since its isoforms
exhibit various apoptosis-related properties, it is believed that the formation of survivin heterodimers
with its isoforms may be important for regulating the function of survivin [8]. Since survivin isoforms
can affect the activity of wild type survivin, and the transcription of this gene is regulated by
HH-GLI signaling, it is important to investigate which factors contribute to the expression of certain
isoforms. In this paper our goal was to examine the role of individual GLI transcription factors in the
transcriptional regulation of survivin isoforms.
2. Materials and Methods
2.1. Generation of Knockout Cell Lines
SKOV-3 cell line [3] was maintained in DMEM supplemented with 10% FBS and
penicillin/streptomycin. The CRISPR/Cas9 system was used to generate the knock-out cell lines.
sgRNA molecules targeting the area surrounding the STG site of GLI1, GLI2, and GLI3 genes were
generated using the online tool at crispr.mit.edu web site. Five top ranking sgRNA molecules were
selected, and the one closest to the ATG site of each gene was selected. The sgRNA oligos were
annealed, phosphorylated and cloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 (plasmid #42230,
Addgene, Watertown, MA, USA) [35] into the BbsI restriction site, and the resulting vectors were
sequenced on the ABI Prism 310 sequencing machine. The oligo sequences are listed in Supplementary
Table S1. The SKOV-3 cell line was transfected with the generated vectors using the Xfect transfection
reagent (Clontech, Mountain View, CA, USA). At 24 h post-transfection, the cells were trypsinized and
plated into 96-well plates at the density of 1 cell/well. Several cell lines were propagated from single
cells, and protein expression for each of the three GLI proteins was examined by Western blot to select
the lines with the best knock-out for each protein.
2.2. Cell Culture Experiments
Cells were plated in 6-well plates, treated with two concentrations of GANT-61 (10 and 20 µM).
The cells were collected 24 h after treatment. For the transfection of GLI1 (pcDNA4NLSMTGLI1,
a kind gift from Prof. F. Aberger, Austria), GLI2 (p4TO6MTGLI2, a kind gift from Prof. M. Stevanovic,
Serbia), GLI3 (pcDNA4/TO/GLI3richtig, a kind gift from Prof. M. Stevanovic, Serbia), and GLI3R
(EGLI3-PHS, a kind gift from Prof. R. Toftgard, Sweden) the cells were seeded in 6-well plates and
transfected the next day with 5 µg of plasmid DNA using the X-fect reagent (Clontech) following the
manufacturer’s instructions.
2.3. Clinical Samples
Forty ovarian carcinoma (OC) samples and nine healthy fallopian tubes (FT) tissue samples
(excised for reasons other than malignant transformations) were collected at the Department of
Obstetrics and Gynaecology, University Hospital Centre Zagreb, School of Medicine, University
of Zagreb. Patient blood samples were also collected. Blood samples collected from 74 healthy
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elderly women with no personal history of ovarian cancer were used as control for comparing
polymorphism frequencies.
All patients gave their informed consent before the samples were taken, and samples were
collected with the approval of the hospital’s Ethical Committee (number of approval 02/21 AG, issued
by the University Hospital Centre Zagreb on March 7th, 2017). The study was carried out following
the rules of the Declaration of Helsinki Principles. All tissue samples taken during surgery were
immediately placed in a vial containing 1 mL RNALater solution (Invitrogen, Carlsbad, CA, USA),
kept at 4 ◦C overnight, and DNA and RNA were extracted the following day. DNA from tissue samples
was extracted by the standard phenol-chloroform method and from blood by the salting out method.
2.4. Western Blot
Proteins were extracted by sonication in RIPA buffer supplemented with protease inhibitors
(Roche, Basel, Switzerland). Protein concentration was determined using the Pierce BCA Protein Assay
Kit (Thermo Fisher, Waltham, MA, USA). Western blot was performed as previously described [36]
using the following primary antibodies: GLI1 (V812, Cell Signaling Technology, 1:1000, Danvers, MA,
USA), GLI2 (ARP31885_T100, Aviva Systems Biology, 1:1000, San Diego, CA, USA), GLI3 (19949-1-AP,
ProteinTech, 1:600, Rosemont, IL, USA), GFP for detection of GFP tagged GLI3R (Abcam ab6556,
1:1000, Cambridge, UK), and β-actin (60008-1-Ig, ProteinTech, 1:4000) and γ-tubulin (Santa Cruz
Biotechnology, sc-7396, 1:500, Dallas, TX, USA) as loading controls.
2.5. Expression Analysis
RNA was extracted using TRIZol reagent (Thermo Fisher) and reverse-transcribed using TaqMan
Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). qRT-PCR was performed
on a CFX96 machine (Bio-Rad Laboratories, Hercules, CA, USA) using Sso Fast EVAGreen Supermix
(Bio-Rad).
The PCR conditions were as follows: initial denaturation at 95 ◦C for 3 min, 40 cycles of 95 ◦C for
15 sec, 61 ◦C for 1 min, and finally melting curve from 70 ◦C to 95 ◦C. All experiments were performed
at least in duplicate. Primer sequences are listed in Supplementary Table S2. Expression levels were
calculated using the 2−∆∆Ct formula, relative to the housekeeping gene TBP [37]. For samples with no
expression of a specific target after 40 cycles of qRT-PCR, the Ct was set to 40 to enable the statistical
analysis of data [38].
2.6. Genotyping
Whole coding region (including alternate exons S 2α, S 2B, and S 3B) was genotyped, including
the six SNPs in the BIRC5 promoter and four SNPs in the 3′UTR region selected from the National
Center for Biotechnology Information SNP database (http://www.ncbi.nlm.nih.gov/snp). Primers
were designed using the Primer3 online tool (http://bioinfo.ut.ee/primer3/) [39]. Thirteen PCR
fragments were analyzed using high resolution melting analysis on High-Resolution Melter (HR-1,
Idaho Technology, Salt Lake City, UT, USA) as described in Cvok et al, 2008 [40] followed by Sanger
sequencing (ABI PRISM 310 Genetic Analyzer, Applied Biosystems). Due to presence of four different
polymorphisms in the PCR product of exon 4 and the beginning of 3′UTR, it was directly sequenced.
PCR primer sequences and cycling conditions are listed in Supplementary Table S3. Due to high GC
content in the DNA sequence of promoter region, in all PCR fragments located in the promoter CG
RICH buffer (Roche) was added.
2.7. Statistical Analysis
D'Agostino–Pearson test was used for testing distribution normality of the expression data.
For variables which showed normal distribution after logarithmic transformation, independent sample
t-test and one-way analysis of variance were used to test the differences in isoforms’ expressions.
Otherwise Mann–Whitney test and Kruskal–Wallis test were used. Nonparametric Spearman rank
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correlation coefficient ($) was used to assess the correlation of expression between various isoforms.
For comparing polymorphism frequencies Fisher’s exact test (2 × 2) and χ2 test (3 × 2) were used.
Two-tailed p values less than 0.05 were considered statistically significant. Statistical analysis was
performed using MedCalc, version 18.2.1 (MedCalc Software bvba, Ostend, Belgium).
3. Results and Discussion
3.1. GLI Regulation of Survivin Isoform Expression
To test the contribution of each GLI protein to the expression levels of five different survivin
isoforms, we generated SKOV-3 knock-out lines for GLI1, GLI2, and GLI3 proteins and examined
the expression of these isoforms by qRT-PCR. All three KO cell lines exhibit reduced levels of full
length GLI proteins, as well as GLI2 and GLI3 repressor forms. However, the band corresponding
to the GLI2∆N isoform is still present in the SKOV-3 GLI2 KO cell line (Supplementary Figure S1).
The expression levels of all isoforms were significantly downregulated in the SKOV-3 GLI1 KO cell
line. In the SKOV-3 GLI2 KO cell line, only the S 3B and S ∆ex3 isoforms were downregulated, whereas
knocking out GLI3 had no effect on either isoform (Figure 2). Therefore, we decided to focus on the
SKOV-3 GLI1 KO line.
Figure 2. Levels of survivin isoform expression in the SKOV-3 GLI KO lines compared with SKOV-3
WT cells. * represents statistically significant downregulation in comparison with the WT cell line
(p < 0.05).
SKOV-3 wild type (WT) and the GLI1 KO lines were treated with two doses of the GLI1/2 inhibitor
GANT-61 to test the responsiveness of different isoforms. GANT-61 showed a dose-dependent additive
effect to knocking out GLI1 on the expression of S WT, S 2α, and S 2B, which suggests that these three
isoforms are regulated by both GLI1 and an additional GANT-61 target, probably GLI2. The S 2B
isoform shows the strongest response to inhibition with GANT-61, and even though it is affected by
the GLI1 KO, it is less pronounced than in the other isoforms, suggesting that this isoform is regulated
primarily by GLI2. The lack of effect on expression of these isoforms in the GLI2 KO cell line may be
due to the persisting GLI2∆N isoform, which is known to be a much more potent activator than the
GLI2 full length protein [41]. The S 3B and S ∆ex3 isoforms do not respond to additional GANT-61
inhibition, suggesting that they are primarily regulated through GLI1 (Figure 3).
Our results correspond to those of Vlcˇkova et al [4], who showed that GLI1 and GLI2 have
a moderate effect on survivin promotor activation and GLI3 displayed no promotor activation. In their
study, they studied the GLI2∆N isoform separately and showed that this GLI2 isoform has the strongest
activation potential.
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Figure 3. Survivin isoform expression levels in the SKOV-3 WT cell line and the SKOV-3 GLI1 KO cell
line after treatment with the GLI1/2 inhibitor GANT-61 for 24h. NT, non-treated samples; G 10µM,
cells treated with 10 µM GANT-61; G 20µM, cells treated with 20 µM GANT-61. * represents statistically
significant downregulation (p < 0.05).
To validate the role of specific GLI transcription factors in the expression of survivin isoforms we
overexpressed all three GLI transcription factors in the SKOV-3 cell line, including the GLI3 repressor
(GLI3R) (Supplementary Figure S2). Transfection of GLI1 and GLI2 expectedly activated the HH-GLI
pathway, detected by the upregulation of GLI1 and PTCH1 genes. Overexpression of GLI3 showed no
effect on HH-GLI pathway activity, whereas overexpression of GLI3R downregulated the pathway
(Figure 4A). Only slight changes in gene expression levels of survivin isoforms were observed upon
GLI transcription factor transfection, probably due to an already high level of activity of these genes in
cancer cells. On the other hand, GLI3R overexpression, which downregulates the HH-GLI signaling
pathway (Figure 4A), leads to a significant decrease in expression of all survivin isoforms, except S 2B
(Figure 4B).
Figure 4. The effect of GLI1, GLI2, GLI3, and GLI3R overexpression in the SKOV-3 WT cell line on
(A) the expression levels of GLI1, GLI2, GLI3, and PTCH1 and (B) the expression levels of survivin
isoforms. * represents statistically significant changes in expression compared with cells transfected
with empty vector.
3.2. Expression of Splice Variants
To verify that the SKOV-3 cell line is the appropriate model for studying survivin isoforms in OC,
we compared basal expression levels of all five isoforms in cells to those in OC tissues. The expression
patterns were shown to be the same (p < 0.001), implying that this cell line is a valid model for studying
survivin isoforms in OC (Figure 5).
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Figure 5. Relative expression of survivin isoforms in the SKOV-3 cell line (circles) and ovarian
carcinoma (OC) tissue samples (triangles).
The mRNA expression of S WT, S 2α, S 2B, S 3B, and S ∆ex3 was analyzed in 29 OC samples and
compared to FT. Isoforms S WT and S 2α were detected in 96.5% of OC samples, S 2B in 58.6%, S 3B in
68.9%, and S ∆ex3 in 89.6% of OC samples. In contrast, the only splice variants detected in healthy
FT samples were the weakly expressed S WT and S 2α. No other isoforms were detected in FT. The
levels of all survivin isoforms expression differed significantly from each other (p < 0.001) (Table 1).
The highest expression was determined for the S WT and S 2α isoforms, while S 2B had the lowest
expression. OC samples showed significantly higher expression of these two isoforms compared to
healthy fallopian tube tissue (p = 0.0001 and p = 0.0015, respectively) (Figure 6).
Figure 6. Relative expression of S WT (A) and S 2α (B) in fallopian tube (FT) and ovarian carcinoma
(OC) samples.
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Table 1. The association of survivin isoform expression in OC samples.
S 2α S 2B S 3B S ∆ex3 - -
0.92 0.69 0.81 0.75
S WT
$
<0.0001 0.002 <0.0001 <0.0001 p
- 0.67 0.80 0.81
S 2α
$
- 0.005 <0.0001 <0.0001 p
- - 0.55 0.67
S 2B
$
- - 0.021 0.004 p
- - - 0.66
S 3B
$
- - - 0.002 p
- - - - - -
Spearman rank correlation coefficient ($)
The expression levels of survivin isoforms was compared to the levels of GLI1, GLI2, and
GLI3 expression which were published previously for the same set of OC tissue samples (data not
shown) [36]. The only isoform which was correlated with the GLI genes was the S 2B isoform,
which correlated with GLI2 expression ($ = 0.55, p = 0.019). Interestingly, in SKOV-3 cells the S 2B
isoform showed significant upregulation only after transfection of GLI2 (Figure 4B), indicating that
this isoform is regulated by GLI2.
3.3. Genotyping
Fifteen different polymorphisms were detected in the analyzed samples (OC and control) (Table 2).
Most of the polymorphisms were located in the 5' and 3′UTR regions including the promoter region.
All polymorphisms were in the Hardy–Weinberg equilibrium. There was no significant difference in
distribution of genotypes and alleles between OC samples and controls for any of variant. However,
c.-235A variant was more frequent in OC but with borderline significance (p = 0.053). Likewise,
the‘frequency of heterozygous genotype c.-235G>A was higher in OC with marginal significance
(p = 0.051) (Supplementary Table S4).
Table 2. BIRC5 polymorphisms in OC samples and healthy controls. MAF, minor allele frequency; OC,
ovarian carcinoma.
Gene Region SNP IDNumber
Nucleotide
Change
MAF in OC
(%)
MAF in
Controls (%) p-Value
promoter rs3764383 c.-1547C>T * 23.1 25.0 0.871
promoter rs143396310 c.-1458C>T 1.3 1.4 1.000
promoter rs8073903 c.-644T>C 26.3 33.1 0.297
promoter rs8073069 c.-625G>C 21.3 22.3 1.000
promoter rs17878731 c.-267G>A 1.3 0.7 1.000
promoter rs17878467 c.-241C>T 5.0 10.8 0.219
promoter rs17887126 c.-235G>A 6.3 1.4 0.053
5′UTR rs9904341 c.-31G>C 48.8 37.2 0.093
intron 2 rs4789551 c.221+209T>C 6.4 4.7 0.756
exon 4 rs2071214 c.9194G>A ** 3.8 3.4 1.000
3′UTR rs17885521 c.9288G>C 1.3 2.0 1.000
3′UTR rs17882627 c.9342G>A 2.5 1.4 0.614
3′UTR rs2239680 c.9386T>C 23.8 23.0 1.000
3′UTR rs1042489 c.9809T>C 25.0 35.8 0.104
3′UTR rs2661694 c.10611C>A 26.3 25.7 1.000
* C is the minor allele, ** G is the minor allele.
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The allele frequencies for polymorphisms were in accordance with previous reports [29,34,42–46]
or in NCBI database (http://www.ncbi.nlm.nih.gov).
3.4. Linkage Disequilibrium
Analysis showed there is a difference in number of variants in linkage disequilibrium between
OC samples and controls. OC cases showed increased non-random association of alleles at multiple
loci. In case of c.-1547C>T and c.9386T>C, these two polymorphisms always appear in the same
combination in all tested OC samples showing complete linkage disequilibrium (r2 = 1.0) (Figure 7).
Figure 7. Pairwise linkage disequilibrium (LD) of eleven BIRC5 sequence variants with highest minor
allele frequency. The location of each sequence variant along the BIRC5 gene is relative to the real
nucleotide position. The number in each diamond indicates the intensity of LD (r2 × 102) between
respective pairs of sequence variants. The LD strength is also represented by shades of gray (0 [white]
< r2 < 1 [black]). (A) Controls. (B) Cases.
LD has often been reported between various BIRC5 polymorphisms. Most of the correlations
found here have already been described [29,34,44,47,48]. Our group recently described the LD between
c.-644C>T and c.9809T>C in breast cancer (submitted). LD between c.235T>C and c.221+209T>C found
in almost total LD, has not been described before.
3.5. Correlation of Splice Variant Expression with Genetic Polymorphisms in OC Patients
Seven polymorphisms showed significant association with expression of survivin isoforms.
c.-1547C>T showed the highest association with splice variant expression
(Supplementary Figure S1). Samples with homozygous c.-1547T/T genotype showed significantly
higher expression of isoforms S 2α (p = 0.016), S 2B (p = 0.036), and S 3B (p = 0.028). Major T allele
was also significantly associated with higher expression of S 2α (p = 0.033), and S 3B (p = 0.045) than
C allele.
c.9194G>A also showed significant association with variant expression
(Supplementary Figure S2). Samples with heterozygous GA genotype had significantly higher
expression of S WT (p = 0.0001) and S 2α (p = 0.0005) than AA genotype. Minor G allele was also
significantly associated with higher expression of S WT (p < 0.0001) and S 2α (p < 0.0001) compared to
A allele.
c.9386T>C and c.10611C>A showed significant association with the expression of S 2α and S 3B
(Supplementary Figure S3). Samples with major c.9386TT genotype had significantly higher expression
of S 2α (p = 0.032) and S 3B (p = 0.036) than TC genotype. Samples with major c.10611CC also had
significantly higher expression of S 2α (P = 0.040) and S 3B (p = 0.036) than CA genotype.
c.-625G>C, c.-235G>A, and c.221+209T>C also showed some significant associations with isoform
expression (Supplementary Figure S4). Samples with minor homozygous c.-625CC genotype had
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significantly lower expression of S 2α in comparison to heterozygous GC genotype. Samples with
major G allele of c.-235G>A (p = 0.047) or major T allele of c.221+209T>C (p = 0.045) had significantly
higher expression of S 3B isoform than the minor alleles.
Association of BIRC5 polymorphisms and expression of survivin isoforms have not been explored
a lot in the literature. There are some reports about the influence of several polymorphisms on total
survivin expression, most notably c.-31G>C [46,48–50], but also c.9386T>C [51] and c.9809T>C [47].
Antonacopoulou et al studied the correlation of c.-31G>C and c.9386C>T with the survivin isoform
expression in colorectal cancer, and they found the same association of c.9386C>T genotypes with the
expression of S 2α [8].
4. Conclusions
We have detected survivin isoform expression (S WT, S 2α, S 2B, S 3B, and S ∆ex3) in the ovarian
cancer cell line SKOV-3, that follows the trend of isoform expression levels in its GLI KO variants and
in ovarian cancer samples (Figure 5). The BIRC5 gene has been recognized as one of the transcriptional
targets of the HH-GLI signaling pathway [4]. The GLI2∆N isoform has been indicated as the main
transcription factor that regulates BIRC5 gene expression. We have previously detected activity of
the HH-GLI pathway in ovarian cancer [36] and therefore we wanted to examine the role of the GLI
transcription factors not only in the regulation of survivin wild type expression, but also its isoforms.
Because of the different roles of certain isoforms and their ability to regulate survivin function after
heterodimer formation it is important to investigate how certain isoforms are regulated. Interestingly,
our results confirm that survivin is regulated by the HH-GLI signaling pathway, but not all isoforms
are regulated in the same manner. More specifically, all isoforms are regulated by GLI1, but isoforms S
WT, S 2α, and S 2B can additionally be inhibited with the GLI1/2 inhibitor GANT-61, suggesting that
these isoforms can also be regulated through other GANT-61 targets, most likely, GLI2.
Seven BIRC5 polymorphisms are also associated with the expression of survivin isoforms.
Therefore, there is an intricate regulation of expression between genetic influence and transcription
factors such as GLI proteins to determine the final expression of survivin isoform expression and their
anti- and pro-apoptotic role that could determine the fate of the cells.
Supplementary Materials: The following are available at http://www.mdpi.com/2073-4409/8/2/128/s1,
Figure S1: Western blots showing the protein expression of GLI1-3 proteins in SKOV-3 knock-out lines; Figure
S2: Western blots showing the overexpression of GLI1-3 proteins in SKOV-3 cell line; Figure S3: Association
between c.-1547C>T and survivin isoform expression; Figure S4: Association between c.9194G>A and survivin
isoform expression; Figure S5: Association between c.9386T>C and c.10611C>A and survivin isoform expression;
Figure S6: Association between c.-625G>C, c.-235G>A and c.221+209T>C and survivin isoform expression. Table
S1: Oligos used for cloning; Table S2: Primer sequences for splice variant expression; Table S3: Sequences of
genotyping primers; Table S4: Association of genotype and allele frequencies.
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